- Home
- RIV vs CADL Comparison
RIV vs CADL Comparison
Compare RIV & CADL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
HOLD
Current Price
$5.73
Company Overview
Basic Information| Metric | RIV | CADL |
|---|---|---|
| Founded | 2015 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 325.4M | 339.8M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | RIV | CADL |
|---|---|---|
| Price | $12.01 | $5.73 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $19.43 |
| AVG Volume (30 Days) | 87.6K | ★ 735.2K |
| Earning Date | 01-01-0001 | 03-12-2026 |
| Dividend Yield | ★ 12.85% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $9.63 | $4.25 |
| 52 Week High | $12.43 | $13.68 |
Technical Indicators
Market Signals| Indicator | RIV | CADL |
|---|---|---|
| Relative Strength Index (RSI) | 61.00 | 47.43 |
| Support Level | $11.79 | $5.91 |
| Resistance Level | $12.04 | $6.62 |
| Average True Range (ATR) | 0.09 | 0.37 |
| MACD | 0.01 | -0.03 |
| Stochastic Oscillator | 84.71 | 18.72 |
Price Performance
Historical Comparison RIV
CADL
About RIV RiverNorth Opportunities Fund Inc.
Rivernorth Opportunities Fund Inc is a diversified, closed-end management investment company. The fund's investment objective is total return consisting of capital appreciation and current income.
About CADL Candel Therapeutics Inc.
Candel Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing viral immunotherapies to help patients fight cancer. The company has established two clinical-stage viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.